XAV-939 inhibits tankyrases and Wnt pathway signaling. XAV exhibits anti-fibrotic activity and shows potential anticancer chemotherapeutic benefit when co-administered with other compounds. XAV-939 decreases nuclear accumulation of β-catenin and decreases c-myc levels, decreasing bleomycin-induced dermal thickening. In both in vitro and in vivo models of cancer, this compound reverses resistance to PI3K and Akt inhibitors.

**References**


**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.